AI saves 82-year old after chemo failed 6 times

It's one of the most important and astonishing scientific breakthroughs of our time. ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ Unsubscribe A Message from The Oxford Club Dear Reader, Check out this amazing story. It involves an 82-year old named Paul with blood cancer. Paul went through six separate rounds of chemo... And all six failed. Then, a new company used AI to designate a new treatment for him. Two years later... Paul was cancer free. It's one of the most important and astonishing scientific breakthroughs of our time. And now... the small company behind the breakthrough is signing massive deals with big pharma. Up to $674 million with Merck... $1.2 billion with Bristol Myers Squibb... and up to an astonishing $5.2 billion to develop 15 potential treatments with Sanofi. We're talking about up to $7 billion worth of deals for a company that's worth a fraction of that amount. The stock trades for less than $10 today. But it might just become the #1 AI company in the world over the next few years. Go here to see the full story. Rachel Gearhart Associate Publisher, The Oxford Club P.S. The same man who called 4 of the top 6 stocks in the markets from 2000 to 2020, is naming this his #1 stock going forward. He explains why here. Thank you for subscribing to DividendStocks.com's daily newsletter for dividend and income investors that covers ex-dividend stocks, new dividend declarations, dividend stock ideas, and the latest market news.   This message is a paid advertisement sent on behalf of The Oxford Club, a third-party advertiser of DividendStocks.com and MarketBeat.     This ad is sent on behalf of The Oxford Club. 105 W Monument St, Baltimore, Maryland 21201. If you would like to opt-out from receiving offers from The Oxford Club please click here.     If you have questions about your subscription, feel free to contact our U.S. based support team via email at contact@marketbeat.com.   If you no longer wish to receive email from DividendStocks.com, you can unsubscribe.   © 2006-2023 American Consumer News, LLC dba MarketBeat. 345 N Reid Place, Suite 620, Sioux Falls, SD 57103. United States.